Cargando…
Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells
BACKGROUND: Synthesis of the hemostatic protein von Willebrand factor (VWF) drives formation of endothelial storage organelles called Weibel‐Palade bodies (WPBs). In the absence of VWF, angiogenic and inflammatory mediators that are costored in WPBs are subject to alternative trafficking routes. In...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6782018/ https://www.ncbi.nlm.nih.gov/pubmed/31624792 http://dx.doi.org/10.1002/rth2.12242 |
_version_ | 1783457482087071744 |
---|---|
author | Schillemans, Maaike Kat, Marije Westeneng, Jurjen Gangaev, Anastasia Hofman, Menno Nota, Benjamin van Alphen, Floris P. J. de Boer, Martin van den Biggelaar, Maartje Margadant, Coert Voorberg, Jan Bierings, Ruben |
author_facet | Schillemans, Maaike Kat, Marije Westeneng, Jurjen Gangaev, Anastasia Hofman, Menno Nota, Benjamin van Alphen, Floris P. J. de Boer, Martin van den Biggelaar, Maartje Margadant, Coert Voorberg, Jan Bierings, Ruben |
author_sort | Schillemans, Maaike |
collection | PubMed |
description | BACKGROUND: Synthesis of the hemostatic protein von Willebrand factor (VWF) drives formation of endothelial storage organelles called Weibel‐Palade bodies (WPBs). In the absence of VWF, angiogenic and inflammatory mediators that are costored in WPBs are subject to alternative trafficking routes. In patients with von Willebrand disease (VWD), partial or complete absence of VWF/WPBs may lead to additional bleeding complications, such as angiodysplasia. Studies addressing the role of VWF using VWD patient–derived blood outgrowth endothelial cells (BOECs) have reported conflicting results due to the intrinsic heterogeneity of patient‐derived BOECs. OBJECTIVE: To generate a VWF‐deficient endothelial cell model using clustered regularly interspaced short palindromic repeats (CRISPR) genome engineering of blood outgrowth endothelial cells. METHODS: We used CRISPR/CRISPR‐associated protein 9 editing in single‐donor cord blood–derived BOECs (cbBOECs) to generate clonal VWF (−/−) cbBOECs. Clones were selected using high‐throughput screening, VWF mutations were validated by sequencing, and cells were phenotypically characterized. RESULTS: Two VWF (−/−) BOEC clones were obtained and were entirely devoid of WPBs, while their overall cell morphology was unaltered. Several WPB proteins, including CD63, syntaxin‐3 and the cargo proteins angiopoietin (Ang)‐2, interleukin (IL)‐6, and IL‐8 showed alternative trafficking and secretion in the absence of VWF. Interestingly, Ang‐2 was relocated to the cell periphery and colocalized with Tie‐2. CONCLUSIONS: CRISPR editing of VWF provides a robust method to create VWF‐ deficient BOECs that can be directly compared to their wild‐type counterparts. Results obtained with our model system confirmed alternative trafficking of several WPB proteins in the absence of VWF and support the theory that increased Ang‐2/Tie‐2 interaction contributes to angiogenic abnormalities in VWD patients. |
format | Online Article Text |
id | pubmed-6782018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67820182019-10-17 Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells Schillemans, Maaike Kat, Marije Westeneng, Jurjen Gangaev, Anastasia Hofman, Menno Nota, Benjamin van Alphen, Floris P. J. de Boer, Martin van den Biggelaar, Maartje Margadant, Coert Voorberg, Jan Bierings, Ruben Res Pract Thromb Haemost Original Articles: Haemostasis BACKGROUND: Synthesis of the hemostatic protein von Willebrand factor (VWF) drives formation of endothelial storage organelles called Weibel‐Palade bodies (WPBs). In the absence of VWF, angiogenic and inflammatory mediators that are costored in WPBs are subject to alternative trafficking routes. In patients with von Willebrand disease (VWD), partial or complete absence of VWF/WPBs may lead to additional bleeding complications, such as angiodysplasia. Studies addressing the role of VWF using VWD patient–derived blood outgrowth endothelial cells (BOECs) have reported conflicting results due to the intrinsic heterogeneity of patient‐derived BOECs. OBJECTIVE: To generate a VWF‐deficient endothelial cell model using clustered regularly interspaced short palindromic repeats (CRISPR) genome engineering of blood outgrowth endothelial cells. METHODS: We used CRISPR/CRISPR‐associated protein 9 editing in single‐donor cord blood–derived BOECs (cbBOECs) to generate clonal VWF (−/−) cbBOECs. Clones were selected using high‐throughput screening, VWF mutations were validated by sequencing, and cells were phenotypically characterized. RESULTS: Two VWF (−/−) BOEC clones were obtained and were entirely devoid of WPBs, while their overall cell morphology was unaltered. Several WPB proteins, including CD63, syntaxin‐3 and the cargo proteins angiopoietin (Ang)‐2, interleukin (IL)‐6, and IL‐8 showed alternative trafficking and secretion in the absence of VWF. Interestingly, Ang‐2 was relocated to the cell periphery and colocalized with Tie‐2. CONCLUSIONS: CRISPR editing of VWF provides a robust method to create VWF‐ deficient BOECs that can be directly compared to their wild‐type counterparts. Results obtained with our model system confirmed alternative trafficking of several WPB proteins in the absence of VWF and support the theory that increased Ang‐2/Tie‐2 interaction contributes to angiogenic abnormalities in VWD patients. John Wiley and Sons Inc. 2019-08-01 /pmc/articles/PMC6782018/ /pubmed/31624792 http://dx.doi.org/10.1002/rth2.12242 Text en © 2019 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles: Haemostasis Schillemans, Maaike Kat, Marije Westeneng, Jurjen Gangaev, Anastasia Hofman, Menno Nota, Benjamin van Alphen, Floris P. J. de Boer, Martin van den Biggelaar, Maartje Margadant, Coert Voorberg, Jan Bierings, Ruben Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells |
title | Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells |
title_full | Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells |
title_fullStr | Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells |
title_full_unstemmed | Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells |
title_short | Alternative trafficking of Weibel‐Palade body proteins in CRISPR/Cas9‐engineered von Willebrand factor–deficient blood outgrowth endothelial cells |
title_sort | alternative trafficking of weibel‐palade body proteins in crispr/cas9‐engineered von willebrand factor–deficient blood outgrowth endothelial cells |
topic | Original Articles: Haemostasis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6782018/ https://www.ncbi.nlm.nih.gov/pubmed/31624792 http://dx.doi.org/10.1002/rth2.12242 |
work_keys_str_mv | AT schillemansmaaike alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT katmarije alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT westenengjurjen alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT gangaevanastasia alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT hofmanmenno alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT notabenjamin alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT vanalphenflorispj alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT deboermartin alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT vandenbiggelaarmaartje alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT margadantcoert alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT voorbergjan alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells AT bieringsruben alternativetraffickingofweibelpaladebodyproteinsincrisprcas9engineeredvonwillebrandfactordeficientbloodoutgrowthendothelialcells |